Pulmonology

The key benefits of FRI technology in respiratory drug development are:

  • More sensitive outcome parameters
  • No need for patient interaction in pre-clinical phase
  • Increased speed of early clinical trials
  • Higher efficiency of translational process

At a cost of $1.6 billion per registered product, the development of respiratory drugs is significantly more expensive than for other drugs.  This is in part attributable to the lack of sensitive outcome parameters for the trials. The currently used parameters fail to clearly demonstrate the therapeutic benefits of newly developed therapies, thereby complicating the registration process.

Application of FRI can have a major positive impact on cost and patient treatment. FLUIDDA’s technology can decrease the cost and development time in the pre-clinical and clinical phases and facilitate the transition between the two phases:

  • In the pre-clinical phase, there is no need for patient involvement when using FRI. Costs are decreased by speeding up the process through the use of realistic animal and patient-specific models. These models are used to assess aerosol deposition patterns as a function of the different parameters (inhaler, inhalation profile, etc.) without patient involvement.
  • In the clinical phase cost reduction is achieved by using more sensitive measurements, such as segmented airway volume changes or changes in CFD-based resistance, which provide more information. This makes it possible to optimize the design of the costly phase III study and identify ineffective therapies early.
  • Using a common parameter, such as an animal or patient-specific model, results in the optimization of the translational process.  Iterations can be performed on inhaler design or particle formulation, resulting in products with a high chance of improving the conditions of the targeted patient population. Feedback from the clinical trials also makes it possible to update the model for future trials with other new products.

5294930287d34-

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

MiRC, LDA

Medical Imaging Research Corporation
Avenida da igreja 42, 6th floor
1700-239 Lisbon
Portugal

MiRC, LDA

Medical Imaging Research Corporation
Avenida da igreja 42, 6th floor
1700-239 Lisbon
Portugal

FLUIDDA, Inc

228 East 45th Street
9th Floor - Suite 9E
New York, NY 10017
United States

FLUIDDA, Inc

228 East 45th Street
9th Floor - Suite 9E
New York, NY 10017
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2017